Clinical Trials

Do you or your child have sickle cell disease and access to a smart phone? This study tests whether a mobile app can help adolescents and young adults who have sickle cell disease take medicine, such as hydroxyurea, correctly and on time. To participate in this study, you or your child must be between 12 and 21 years old, have sickle cell disease, and be currently taking hydroxyurea. This study takes place in Chicago, Illinois.

Are you an adult with sickle cell disease who’s recently had a vaso-occlusive episode? This study investigates better ways for emergency departments (EDs) to manage vaso-occlusive episodes, or pain crises, in people with sickle cell disease. This study is incorporating “Individualized Pain Plans” into patients’ electronic health records to allow for faster and more accurate treatment in the ED. To participate in this study, you must be between the ages of 18 and 45 and have sickle cell disease. You must also have had at least one visit to a participating ED in the past 90 days due to pain from a vaso-occlusive episode and at least one visit at the study site sickle cell disease clinic within the past 12 months. This study takes place in multiple locations in the United States.

Do you or your child have sickle cell disease? This study aims to develop a mathematical equation to estimate the functioning of the kidneys in children and adults with sickle cell disease. To participate in this study, you or your child must be between 5 and 50 years old. This study takes place in Birmingham, Alabama; Chicago, Illinois; and Memphis, Tennessee.

Are you an adult with sickle cell disease who doesn't experience pain episodes? This study uses machine learning to identify sickle cell disease patients who may be at increased risk of chronic kidney disease. To participate in this study, you must be between 18 and 65 years old with sickle cell disease and not experiencing any painful episodes. This study takes place in Chicago, Illinois, Winston-Salem, North Carolina, and Memphis, Tennessee.

Are you an adult with heart failure and right bundle branch block (RBBB)? This study will evaluate the effectiveness and benefit of His-bundle-pacing enhanced cardiac resynchronization therapy (His-CRT) versus cardiac resynchronization therapy (BiV-CRT). This study is located in Rochester, New York.

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

Are you between 14 and 22 weeks pregnant, and think that you might have obstructive sleep apnea (OSA) ? This study is testing whether using CPAP to treat obstructive sleep apnea in pregnant women can help lower the risk of hypertensive disorders during pregnancy. To participate in this study, you must be at least 18 years old. This study takes place in multiple locations in the United States.

Are you an adult who has been diagnosed with sleep apnea, prediabetes, and overweight or obesity? This study aims to understand how sleep apnea raises the risk of diabetes. The study will test whether treating sleep apnea with medicines or continuous positive airway pressure (CPAP) helps lower the risk of diabetes in people who have prediabetes. To participate in this study, you must be 20 to 65 years old. This study takes place in Chicago, Illinois.

Are you an African American adult with type 2 diabetes? This study is testing whether mindfulness meditation can help reduce stress and improve sleep. Participants will attend eight meditation classes in person or online and will receive regular text messages to remind them to practice meditation techniques at home. This study takes place in Chicago, Illinois.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.